Serum Chemokine CXCL7 as a Potential Novel Biomarker for Obstructive Colorectal Cancer

Abstract

Due to the lack of typical symptoms and signs and sensitive indicators for early diagnosis of obstructive colorectal cancer (OCRC), it is critically needed to find new novel biomarkers to ameliorate the management of OCRC patients. In this study, 472 blood samples were collected and measured by enzyme-linked immunosorbent assay (ELISA) to investigate the value of serum chemokine ligand 7 (CXCL7) in diagnosis and prognosis for OCRC patients. The median concentrations of CXCL7 in non-OCRC and OCRC were both higher than that in controls (both P < 0.05). Importantly, the median serum concentration of CXCL7 in OCRC was also higher than that in non-OCRC (P < 0.001). In all OCRC patients, the area under the curve (AUC) of CXCL7 was 0.918 with a sensitivity of 86.54% and a specificity of 81.87%. Similarly, the AUC of CXCL7 was 0.684 when the diagnostic test was performed between OCRC and CRC patients. CXCL7 had a higher AUC than other markers. The concentration of CXCL7 in 40 postoperative OCRC patients was higher than normal people and lower than preoperative patients. The median survival time was 62.00 months and the 5-year overall survival (OS) rate of the patients was 51.80% in all 155 OCRC patients. Multivariate Cox proportional hazard regression model analysis showed that high CXCL7 in serum was independent factors associated with poor OS of OCRC patients (HR = 2.216, P = 0.032). These results demonstrate that serum CXCL7 may be a potential biomarker both in diagnosis and prognosis for OCRC patients.

Screening and identification of biomarkers associated with the immune infiltration of intracerebral hemorrhage

“…PPBP is released from activated platelets and is proved to be potential novel biomarker for multiple tumors. 35 , 36 It had been demonstrated that in breast cancer, PPBP, as an important immune cytokine, was secreted by tumor monocytes and played an important role in cancer cell migration, invasion, and metastasis. After PPBP antibody was administered, the abundance of M2 macrophages in the tumor microenvironment was significantly reduced, which reduced tumor growth and distant metastasis.…”

The Chemokine CXCL7 Is Related to Angiogenesis and Associated With Poor Prognosis in Colorectal Cancer Patients

“…Previously we have focused on CXCL7 in serum from CRC patients (30), and its potential application to prognosis of obstructive colorectal cancer (33); however, the relationship between CXCL7 and angiogenesis has not previously been evaluated. In recent years, the role of chemokines in regulating angiogenesis has been revealed in several studies (52,53), including the ability of CCL19 to suppress angiogenesis by downregulating VEGF-A expression in CRC cells (53).…”

“…5) The patient's clinical data was relatively complete. Other terms and selection criteria for healthy participants were described in our previous study (30,33). These criteria were met by 200 patients.…”

“…Our previous study showed that CXCL7 is highly expressed in CRC with poor prognosis (30,33). However, the role of CXCL7 in angiogenesis is unknown.…”

Highly multiplexed targeted plasma proteomics quantifies several hundred blood proteins in serum from colorectal carcinoma patients

“…Of those only the A2M, C1QBC4BPA, CD5L, CRPIGFBP3, TF, and SerpinA1 are specific to CRC tumor samples (supplemental figure 4). An analysis of the current literature revealed that A1AT 17 , ICAM2 18 , IGF2 19 , F13A 20 , CXCL7 21 , and SHBG 22 have been previously found to be associated with colon cancer.…”